{"id":4949,"date":"2022-07-25T06:51:13","date_gmt":"2022-07-25T06:51:13","guid":{"rendered":"https:\/\/preprod.treefrog.fr\/?p=4949"},"modified":"2022-07-25T07:31:47","modified_gmt":"2022-07-25T07:31:47","slug":"peter-nell-joins-treefrog-therapeutics-as-independent-board-member","status":"publish","type":"post","link":"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/","title":{"rendered":"Peter Nell joins TreeFrog Therapeutics as Independent Board Member"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"4949\" class=\"elementor elementor-4949\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-d7b2300 elementor-section-boxed elementor-section-height-default elementor-section-height-default parallax_section_no qode_elementor_container_no\" data-id=\"d7b2300\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-daf4e54\" data-id=\"daf4e54\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-11df341 elementor-widget elementor-widget-text-editor\" data-id=\"11df341\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Bordeaux, France \/ July 7th, 2022<\/strong> \u2013 Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell &amp; gene therapy field over the past ten years and is currently building a new gene editing biotech company. He has worked for over 16 years at Bayer Healthcare, both in the US and Germany, moving from therapeutic research in chemistry (co-inventor of Letermovir and Neladenoson) to leadership positions in business development &amp; licensing and strategic marketing. In 2016, he co-founded Casebia Therapeutics, a joint venture between Bayer and CRISPR Therapeutics developing CRISPR\/Cas9-based gene therapies. Following Casebia\u2019s acquisition by CRISPR Therapeutics in 2019, Peter joined \u201cCRISPR platform\u201d company Mammoth Biosciences as Chief Business Officer and Head of Therapeutics Strategy, initiating collaborations with Vertex and Bayer and supporting fundraising ($195m Series C\/D) while the company grew from 20 to 150 employees.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-b737727 elementor-section-boxed elementor-section-height-default elementor-section-height-default parallax_section_no qode_elementor_container_no\" data-id=\"b737727\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-010545c\" data-id=\"010545c\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2cd6b2e elementor-widget elementor-widget-video\" data-id=\"2cd6b2e\" data-element_type=\"widget\" data-settings=\"{&quot;youtube_url&quot;:&quot;https:\\\/\\\/youtu.be\\\/kCSwGjUWGxA&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}\" data-widget_type=\"video.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-wrapper elementor-open-inline\">\n\t\t\t<div class=\"elementor-video\"><\/div>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-f62c75b elementor-widget elementor-widget-text-editor\" data-id=\"f62c75b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><em>Interview of Peter Nell, Independent Board Member, TreeFrog Therapeutics<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f494da0 elementor-widget elementor-widget-text-editor\" data-id=\"f494da0\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>\u201cPeter is a great addition to our board. He brings an extensive experience in the construction of therapeutic alliances and deep knowledge of the cell &amp; gene therapy ecosystem in the USA \u2013 two strategic areas for TreeFrog Therapeutics. And as we progress the C-Stem technology with the addition of gene editing competencies, his expertise in these technologies such as CRISPR will be invaluable\u201d said Frederic Desdouits, CEO, TreeFrog Therapeutics.<\/p><p>\u201cI am thrilled to have Peter join our team.\u00a0 As we grow our company and capabilities, we intend to create a portfolio of in-house and partnered programs, and Peter is the perfect profile to help us achieve this goal. \u00bb Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics<\/p><p>\u201cI feel very honored having been selected as an independent board member at TreeFrog Therapeutics as the company addresses an area of high need to create meaningful cell therapy approaches to combat severe diseases. Coming from Europe I am excited to see a biotech from France increasing their impact and personally being given the opportunity to contribute to this success story with my knowledge and experience,\u201d said Peter Nell.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a7d708f elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"a7d708f\" data-element_type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-363b813 elementor-widget elementor-widget-text-editor\" data-id=\"363b813\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h5><strong>About TreeFrog Therapeutics<\/strong><br><\/h5>\n<p>TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem\u2122 technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 80 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline in regenerative medicine and immuno-oncology. The company is currently opening technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of C-Stem\u2122 and build strategic alliances with leading academic, biotech and industry players in the field of cell therapy.<br><br><\/p><h5><strong>Media Contact:<\/strong><\/h5>\n<p>Pierre-Emmanuel Gaultier<br>+ 33 6 45 77 42 58<br><a href=\"mailto:pierre@treefrog.fr\">pierre@treefrog.fr<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Bordeaux, France \/ July 7th, 2022 \u2013 Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell &amp; gene therapy field over the past ten years and is currently building a new&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4961,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[12,13],"tags":[],"aioseo_notices":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Peter Nell joins TreeFrog Therapeutics as Independent Board Member - TreeFrog Therapeutics I iPS-derived cell therapies<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peter Nell joins TreeFrog Therapeutics as Independent Board Member - TreeFrog Therapeutics I iPS-derived cell therapies\" \/>\n<meta property=\"og:description\" content=\"Bordeaux, France \/ July 7th, 2022 \u2013 Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell &amp; gene therapy field over the past ten years and is currently building a new...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/\" \/>\n<meta property=\"og:site_name\" content=\"TreeFrog Therapeutics I iPS-derived cell therapies\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-25T06:51:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-25T07:31:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/preprod.treefrog.fr\/wp-content\/uploads\/2022\/07\/Miniature-YT-Peter-Nell.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Piergueritona\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/\",\"url\":\"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/\",\"name\":\"Peter Nell joins TreeFrog Therapeutics as Independent Board Member - TreeFrog Therapeutics I iPS-derived cell therapies\",\"isPartOf\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/#website\"},\"datePublished\":\"2022-07-25T06:51:13+00:00\",\"dateModified\":\"2022-07-25T07:31:47+00:00\",\"author\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\"},\"breadcrumb\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/preprod.treefrog.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peter Nell joins TreeFrog Therapeutics as Independent Board Member\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#website\",\"url\":\"https:\/\/preprod.treefrog.fr\/\",\"name\":\"TreeFrog Therapeutics I iPS-derived cell therapies\",\"description\":\"Cell Therapy for All\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/preprod.treefrog.fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\",\"name\":\"Piergueritona\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g\",\"caption\":\"Piergueritona\"},\"sameAs\":[\"https:\/\/preprod.treefrog.fr\"],\"url\":\"https:\/\/preprod.treefrog.fr\/author\/piergueritona\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Peter Nell joins TreeFrog Therapeutics as Independent Board Member - TreeFrog Therapeutics I iPS-derived cell therapies","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Peter Nell joins TreeFrog Therapeutics as Independent Board Member - TreeFrog Therapeutics I iPS-derived cell therapies","og_description":"Bordeaux, France \/ July 7th, 2022 \u2013 Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell &amp; gene therapy field over the past ten years and is currently building a new...","og_url":"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/","og_site_name":"TreeFrog Therapeutics I iPS-derived cell therapies","article_published_time":"2022-07-25T06:51:13+00:00","article_modified_time":"2022-07-25T07:31:47+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/preprod.treefrog.fr\/wp-content\/uploads\/2022\/07\/Miniature-YT-Peter-Nell.jpg","type":"image\/jpeg"}],"author":"Piergueritona","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/","url":"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/","name":"Peter Nell joins TreeFrog Therapeutics as Independent Board Member - TreeFrog Therapeutics I iPS-derived cell therapies","isPartOf":{"@id":"https:\/\/preprod.treefrog.fr\/#website"},"datePublished":"2022-07-25T06:51:13+00:00","dateModified":"2022-07-25T07:31:47+00:00","author":{"@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220"},"breadcrumb":{"@id":"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/preprod.treefrog.fr\/peter-nell-joins-treefrog-therapeutics-as-independent-board-member\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/preprod.treefrog.fr\/"},{"@type":"ListItem","position":2,"name":"Peter Nell joins TreeFrog Therapeutics as Independent Board Member"}]},{"@type":"WebSite","@id":"https:\/\/preprod.treefrog.fr\/#website","url":"https:\/\/preprod.treefrog.fr\/","name":"TreeFrog Therapeutics I iPS-derived cell therapies","description":"Cell Therapy for All","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/preprod.treefrog.fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220","name":"Piergueritona","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g","caption":"Piergueritona"},"sameAs":["https:\/\/preprod.treefrog.fr"],"url":"https:\/\/preprod.treefrog.fr\/author\/piergueritona\/"}]}},"_links":{"self":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/4949"}],"collection":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/comments?post=4949"}],"version-history":[{"count":17,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/4949\/revisions"}],"predecessor-version":[{"id":4968,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/4949\/revisions\/4968"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/media\/4961"}],"wp:attachment":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/media?parent=4949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/categories?post=4949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/tags?post=4949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}